Tyruko (natalizumab-sztn), a biosimilar to Tysabri (natalizumab), has been made available by Sandoz, according to developer Polpharma Biologics.

An insurance company repeatedly denied a Wisconsin woman coverage for a medication her doctor prescribed to treat her ...

Contineum Therapeutics (CTNM) shares fell following the results from its mid-stage trial of PIPE-307, a treatment aimed at ...

Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with a common form of multiple sclerosis. | Contineum Therapeutics’ M1 receptor ...

Contineum Therapeutics said a trial of its treatment for relapsing-remitting multiple sclerosis didn't meet its primary or secondary efficacy endpoints. The San Diego biopharmaceutical company said ...

—To some extent, yes, say the results of a recent systematic review and meta-analysis. But were escalation therapies any more effective than platform therapies in boosting cognition? Share on Facebook ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Results from the EVOLVE-MS-1 study show ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...

Good physical performance is associated with better cognition in people with relapsing-remitting MS, according to a recent study by the University of Eastern Finland. Good functional capacity was also ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Multiple ...